1. Home
  2. ZSQR vs CNTB Comparison

ZSQR vs CNTB Comparison

Compare ZSQR & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Z Squared Inc. Common Stock

ZSQR

Z Squared Inc. Common Stock

N/A

Current Price

$1.85

Market Cap

147.9M

Sector

Finance

ML Signal

N/A

Logo Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited

N/A

Current Price

$0.62

Market Cap

140.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZSQR
CNTB
Founded
2022
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
147.9M
140.4M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ZSQR
CNTB
Price
$1.85
$0.62
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $5.71
AVG Volume (30 Days)
303.6K
★ 599.6K
Earning Date
12-01-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 50.27
N/A
EPS
★ N/A
N/A
Revenue
★ $1,363,045.00
$64,000.00
Revenue This Year
N/A
$7,473.67
Revenue Next Year
N/A
$240.46
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.83
$0.55
52 Week High
$16.62
$3.82

Technical Indicators

Market Signals
Indicator
ZSQR
CNTB
Relative Strength Index (RSI) 30.02 36.76
Support Level N/A N/A
Resistance Level $4.64 $2.62
Average True Range (ATR) 0.42 0.07
MACD -0.12 0.01
Stochastic Oscillator 1.68 33.75

Price Performance

Historical Comparison
ZSQR
CNTB

About ZSQR Z Squared Inc. Common Stock

Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Share on Social Networks: